These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
103 related items for PubMed ID: 6968460
1. Inhibitors of fibrinolysis in amniotic fluid. Walker JE, Campbell DM, Ogston D. Thromb Haemost; 1980 Aug 29; 44(1):32-4. PubMed ID: 6968460 [Abstract] [Full Text] [Related]
2. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2. Perides G, Noring R, Klempner MS. Biochem Biophys Res Commun; 1996 Feb 27; 219(3):690-5. PubMed ID: 8645243 [Abstract] [Full Text] [Related]
3. The inhibition by plasma of urokinase and tissue activator-induced fibrinolysis in pregnancy and the puerperium. Walker JE, Gow L, Campbell DM, Ogston D. Thromb Haemost; 1983 Feb 28; 49(1):21-3. PubMed ID: 6221434 [Abstract] [Full Text] [Related]
11. The inhibition of tissue activator and urokinase by human plasma. Walker JE, Ogston D. Thromb Haemost; 1982 Jun 28; 47(3):265-8. PubMed ID: 6180497 [Abstract] [Full Text] [Related]
12. Role of alpha 2-plasmin inhibitor in the appearance of fibrinolytic activity during urokinase administration, and an evaluation of the optimal urokinase dosage. Hayashi S, Yamada K. Thromb Res; 1979 Jun 28; 16(3-4):393-400. PubMed ID: 92817 [No Abstract] [Full Text] [Related]
13. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. Vaziri ND, Gonzales EC, Shayestehfar B, Barton CH. J Lab Clin Med; 1994 Jul 28; 124(1):118-24. PubMed ID: 7518491 [Abstract] [Full Text] [Related]
14. Effect of phenylglyoxal-modified alpha2-antiplasmin on urokinase-induced fibrinolysis. Lee KN, Lee SC, Jackson KW, Tae WC, Schwartzott DG, McKee PA. Thromb Haemost; 1998 Oct 28; 80(4):637-44. PubMed ID: 9798984 [Abstract] [Full Text] [Related]
15. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Munkvad S. Dan Med Bull; 1993 Sep 28; 40(4):383-408. PubMed ID: 8222763 [Abstract] [Full Text] [Related]
16. Natural protease inhibitors to fibrinolysis in liver diseases. Arnman R, Gyzander E, Hedner U, Olsson R, Teger-Nilsson AC. Hepatogastroenterology; 1980 Aug 28; 27(4):254-8. PubMed ID: 6162766 [Abstract] [Full Text] [Related]
17. Serum inhibitors in fibrinolysis. Gallimore MJ. Br J Haematol; 1975 Oct 28; 31(2):217-31. PubMed ID: 53065 [Abstract] [Full Text] [Related]
18. Post-traumatic plasminogenesis in intraarticular exudate in the knee joint. Rość D, Powierza W, Zastawna E, Drewniak W, Michalski A, Kotschy M. Med Sci Monit; 2002 May 28; 8(5):CR371-8. PubMed ID: 12011780 [Abstract] [Full Text] [Related]
19. The rapid inhibition of urokinase by plasma from pregnant women at risk for abruptio placenta. Lottenberg R, Willis DC. Thromb Res; 1986 Dec 15; 44(6):807-15. PubMed ID: 2432678 [Abstract] [Full Text] [Related]
20. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes. Rość D, Kremplewska-Nalezyta E, Gadomska G, Zastawna E, Michalski A, Drewniak W. Med Sci Monit; 2000 Dec 15; 6(4):684-91. PubMed ID: 11208392 [Abstract] [Full Text] [Related] Page: [Next] [New Search]